Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration.
DPYSL2
NAP1L1
TUFM
cell migration
cytotoxicity
glioblastoma
glioblastoma stem cells
nanobodies
vimentin
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
07
2019
accepted:
04
03
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
20
5
2020
Statut:
epublish
Résumé
Glioblastoma is a particularly common and very aggressive primary brain tumour. One of the main causes of therapy failure is the presence of glioblastoma stem cells that are resistant to chemotherapy and radiotherapy, and that have the potential to form new tumours. This study focuses on validation of eight novel antigens, TRIM28, nucleolin, vimentin, nucleosome assembly protein 1-like 1 (NAP1L1), mitochondrial translation elongation factor (EF-TU) (TUFM), dihydropyrimidinase-related protein 2 (DPYSL2), collapsin response mediator protein 1 (CRMP1) and Aly/REF export factor (ALYREF), as putative glioblastoma targets, using nanobodies. Expression of these eight antigens was analysed at the cellular level by qPCR, ELISA and immunocytochemistry, and in tissues by immunohistochemistry. The cytotoxic effects of the nanobodies were determined using AlamarBlue and water-soluble tetrazolium tests. Annexin V/propidium iodide tests were used to determine apoptotsis/necrosis of the cells in the presence of the nanobodies. Cell migration assays were performed to determine the effects of the nanobodies on cell migration. NAP1L1 and CRMP1 were significantly overexpressed in glioblastoma stem cells in comparison with astrocytes and glioblastoma cell lines at the mRNA and protein levels. Vimentin, DPYSL2 and ALYREF were overexpressed in glioblastoma cell lines only at the protein level. The functional part of the study examined the cytotoxic effects of the nanobodies on glioblastoma cell lines. Four of the nanobodies were selected in terms of their specificity towards glioblastoma cells and protein overexpression: anti-vimentin (Nb79), anti-NAP1L1 (Nb179), anti-TUFM (Nb225) and anti-DPYSL2 (Nb314). In further experiments to optimise the nanobody treatment schemes, to increase their effects, and to determine their impact on migration of glioblastoma cells, the anti-TUFM nanobody showed large cytotoxic effects on glioblastoma stem cells, while the anti-vimentin, anti-NAP1L1 and anti-DPYSL2 nanobodies were indicated as agents to target mature glioblastoma cells. The anti-vimentin nanobody also had significant effects on migration of mature glioblastoma cells. Nb79 (anti-vimentin), Nb179 (anti-NAP1L1), Nb225 (anti-TUFM) and Nb314 (anti-DPYSL2) nanobodies are indicated for further examination for cell targeting. The anti-TUFM nanobody, Nb225, is particularly potent for inhibition of cell growth after long-term exposure of glioblastoma stem cells, with minor effects seen for astrocytes. The anti-vimentin nanobody represents an agent for inhibition of cell migration.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastoma is a particularly common and very aggressive primary brain tumour. One of the main causes of therapy failure is the presence of glioblastoma stem cells that are resistant to chemotherapy and radiotherapy, and that have the potential to form new tumours. This study focuses on validation of eight novel antigens, TRIM28, nucleolin, vimentin, nucleosome assembly protein 1-like 1 (NAP1L1), mitochondrial translation elongation factor (EF-TU) (TUFM), dihydropyrimidinase-related protein 2 (DPYSL2), collapsin response mediator protein 1 (CRMP1) and Aly/REF export factor (ALYREF), as putative glioblastoma targets, using nanobodies.
METHODS
METHODS
Expression of these eight antigens was analysed at the cellular level by qPCR, ELISA and immunocytochemistry, and in tissues by immunohistochemistry. The cytotoxic effects of the nanobodies were determined using AlamarBlue and water-soluble tetrazolium tests. Annexin V/propidium iodide tests were used to determine apoptotsis/necrosis of the cells in the presence of the nanobodies. Cell migration assays were performed to determine the effects of the nanobodies on cell migration.
RESULTS
RESULTS
NAP1L1 and CRMP1 were significantly overexpressed in glioblastoma stem cells in comparison with astrocytes and glioblastoma cell lines at the mRNA and protein levels. Vimentin, DPYSL2 and ALYREF were overexpressed in glioblastoma cell lines only at the protein level. The functional part of the study examined the cytotoxic effects of the nanobodies on glioblastoma cell lines. Four of the nanobodies were selected in terms of their specificity towards glioblastoma cells and protein overexpression: anti-vimentin (Nb79), anti-NAP1L1 (Nb179), anti-TUFM (Nb225) and anti-DPYSL2 (Nb314). In further experiments to optimise the nanobody treatment schemes, to increase their effects, and to determine their impact on migration of glioblastoma cells, the anti-TUFM nanobody showed large cytotoxic effects on glioblastoma stem cells, while the anti-vimentin, anti-NAP1L1 and anti-DPYSL2 nanobodies were indicated as agents to target mature glioblastoma cells. The anti-vimentin nanobody also had significant effects on migration of mature glioblastoma cells.
CONCLUSION
CONCLUSIONS
Nb79 (anti-vimentin), Nb179 (anti-NAP1L1), Nb225 (anti-TUFM) and Nb314 (anti-DPYSL2) nanobodies are indicated for further examination for cell targeting. The anti-TUFM nanobody, Nb225, is particularly potent for inhibition of cell growth after long-term exposure of glioblastoma stem cells, with minor effects seen for astrocytes. The anti-vimentin nanobody represents an agent for inhibition of cell migration.
Identifiants
pubmed: 32426045
doi: 10.1177/1758835920915302
pii: 10.1177_1758835920915302
pmc: PMC7222267
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920915302Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Crit Rev Oncol Hematol. 2018 May;125:89-101
pubmed: 29650282
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
RNA Biol. 2012 Jun;9(6):799-808
pubmed: 22617883
Trends Biochem Sci. 2017 Apr;42(4):297-311
pubmed: 28118948
Theranostics. 2019 Oct 15;9(25):7772-7791
pubmed: 31695800
Bioconjug Chem. 2019 Feb 20;30(2):273-283
pubmed: 30525488
Oncotarget. 2017 Jul 4;8(27):44141-44158
pubmed: 28498803
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
PLoS One. 2010 Mar 22;5(3):e9804
pubmed: 20339552
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
Appl Immunohistochem Mol Morphol. 2018 May/Jun;26(5):337-344
pubmed: 27556820
Semin Pediatr Neurol. 2015 Mar;22(1):40-8
pubmed: 25976260
Mol Cancer Ther. 2012 Apr;11(4):1017-25
pubmed: 22319202
J Neurooncol. 2015 May;123(1):35-42
pubmed: 25862007
Nature. 2012 Aug 23;488(7412):522-6
pubmed: 22854781
BMC Mol Biol. 2009 Mar 03;10:17
pubmed: 19257903
PLoS One. 2014 Nov 24;9(11):e113688
pubmed: 25419715
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
Methods Mol Biol. 2012;907:145-76
pubmed: 22907350
FASEB J. 2012 Oct;26(10):3969-79
pubmed: 22730440
Curr Mol Pharmacol. 2012 Jan;5(1):102-14
pubmed: 22122467
Nat Rev Mol Cell Biol. 2014 Jul;15(7):465-81
pubmed: 24954209
Oncotarget. 2015 Dec 1;6(38):40998-1017
pubmed: 26517510
Front Cell Neurosci. 2014 Oct 21;8:344
pubmed: 25374510
Nat Rev Mol Cell Biol. 2016 Jan;17(1):41-54
pubmed: 26670016
Neuroscience. 2011 Sep 8;190:37-42
pubmed: 21683126
Database (Oxford). 2014 Feb 25;2014:bau012
pubmed: 24573882
Br J Radiol. 2012 Sep;85(1017):e729-33
pubmed: 22215883
Chem Commun (Camb). 2011 Dec 14;47(46):12547-9
pubmed: 22020088
CA Cancer J Clin. 2010 May-Jun;60(3):166-93
pubmed: 20445000
Oncogene. 2017 Jan 26;36(4):546-558
pubmed: 27321179
Mol Neurobiol. 2018 May;55(5):4403-4416
pubmed: 28660485
Cell Mol Life Sci. 2011 Sep;68(18):3033-46
pubmed: 21637948
Biochimie. 2015 Jun;113:78-85
pubmed: 25866190
Curr Opin Endocrinol Diabetes Obes. 2009 Feb;16(1):72-8
pubmed: 19115524
Cancer Res. 2008 Jul 15;68(14):5706-15
pubmed: 18632623
J Proteomics. 2011 Dec 21;75(2):339-51
pubmed: 21843667
Int J Mol Sci. 2018 May 04;19(5):
pubmed: 29734672
Artif Cells Nanomed Biotechnol. 2016 Sep;44(6):1365-73
pubmed: 26046399
J Control Release. 2020 Jan 10;317:34-42
pubmed: 31734445
Oncotarget. 2018 Apr 3;9(25):17282-17299
pubmed: 29707108
Oncotarget. 2016 Jan 5;7(1):593-609
pubmed: 26573230
Cancer Res. 2009 Nov 15;69(22):8545-54
pubmed: 19903856
BioDrugs. 2020 Feb;34(1):11-26
pubmed: 31686399
FEBS Lett. 2016 Apr;590(8):1064-75
pubmed: 27010360
Cancer Epidemiol. 2013 Feb;37(1):71-8
pubmed: 22959342
Mol Psychiatry. 2015 Sep;20(9):1037-45
pubmed: 26077693
Nucleic Acids Res. 2012 Jan;40(Database issue):D1144-9
pubmed: 22086960
Pathology. 2012 Oct;44(6):506-12
pubmed: 22772342
Nucleic Acids Res. 2017 Jan 4;45(D1):D158-D169
pubmed: 27899622
Nanomedicine. 2014 Jan;10(1):35-44
pubmed: 23891984
Nat Rev Cancer. 2008 Aug;8(8):632-45
pubmed: 18580951
Mol Clin Oncol. 2013 Nov;1(6):935-941
pubmed: 24649273
FASEB J. 2002 Feb;16(2):240-2
pubmed: 11772942
Theranostics. 2014 Jan 29;4(4):386-98
pubmed: 24578722
J Neurooncol. 2012 May;108(1):59-67
pubmed: 22382782
J Neurooncol. 2016 Jan;126(1):19-26
pubmed: 26476730
J Control Release. 2016 Dec 10;243:29-42
pubmed: 27693428
Protein Sci. 2002 Mar;11(3):500-15
pubmed: 11847273
Int J Cancer. 2011 Dec 1;129(11):2744-55
pubmed: 21538350
Genomics. 2019 Jan;111(1):103-113
pubmed: 29355597
Bioconjug Chem. 1999 May-Jun;10(3):406-11
pubmed: 10346871
Methods Mol Biol. 2017;1601:1-17
pubmed: 28470513
Int J Pharm. 2017 Oct 5;531(1):372-388
pubmed: 28755993
Nanoscale. 2015 Mar 12;7(12):5350-62
pubmed: 25721131
Trends Cell Biol. 2007 Feb;17(2):80-6
pubmed: 17157503
Mol Imaging Biol. 2017 Dec;19(6):867-877
pubmed: 28409338
J Neurochem. 2005 Nov;95(4):1201-14
pubmed: 16271053
Biochem Biophys Res Commun. 2017 Jan 22;482(4):597-603
pubmed: 27864146
BMC Cancer. 2011 Feb 17;11:77
pubmed: 21329510
Cell Rep. 2018 Feb 27;22(9):2279-2293
pubmed: 29490266
Nat Rev Mol Cell Biol. 2012 Dec;13(12):780-8
pubmed: 23175281
Physiol Genomics. 2014 Jul 1;46(13):467-81
pubmed: 24803679
Int J Legal Med. 2012 Nov;126(6):943-52
pubmed: 23010907
Genome Biol. 2016 Jun 10;17(1):125
pubmed: 27287018
Breast Cancer. 2014 Nov;21(6):715-23
pubmed: 23381229
Nanomedicine (Lond). 2015 Jan;10(1):161-74
pubmed: 25597775
Nat Rev Cancer. 2011 Oct 07;11(11):792-804
pubmed: 21979307
Expert Opin Biol Ther. 2005 Jan;5(1):111-24
pubmed: 15709914
FEBS Lett. 1997 Sep 15;414(3):521-6
pubmed: 9323027
Nano Converg. 2018 Nov 30;5(1):35
pubmed: 30499047
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318